Table 2.
Risk factors for motor and sensory peripheral neuropathy (n = 127)
| Risk factors | Motor PN |
Sensory PN |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| present, n (%) | absent, n (%) | HR | 95% CI | p value | present, n (%) | absent, n (%) | HR | 95% CI | p value | |||||||||||
| Type of docetaxel-based chemotherapy | ||||||||||||||||||||
| AC→T | 6 (15.0) | 9 (10.3) | 1.00 | 5 (18.5) | 10 (10.0) | 1.00 | ||||||||||||||
| TAC | 5 (12.5) | 14 (16.1) | 0.70 | 0.21–2.30 | 0.14 | 3 (11.1) | 16 (16.0) | 0.50 | 0.12–2.11 | 0.34 | ||||||||||
| TCH | 7 (17.5) | 21 (24.1) | 0.65 | 0.22–2.00 | 0.55 | 3 (11.1) | 25 (25.0) | 0.32 | 0.08–1.40 | 0.13 | ||||||||||
| TC | 22 (55.0) | 43 (49.4) | 2.74 | 0.70–10.76 | 0.46 | 16 (59.3) | 49 (49.0) | 4.27 | 0.81–22.60 | 0.09 | ||||||||||
| Cumulative dose of docetaxel | ||||||||||||||||||||
| ≤300 mg/m2 | 19 (47.5) | 45 (51.7) | 1.00 | 13 (48.1) | 51 (51.0) | 1.00 | ||||||||||||||
| >300 mg/m2 | 21 (52.5) | 42 (48.3) | 3.58 | 1.10–11.64 | <0.05 | 14 (51.9) | 49 (49.0) | 7.20 | 1.70–30.53 | <0.01 | ||||||||||
| Diabetes | ||||||||||||||||||||
| No | 34 (85.0) | 78 (89.7) | 1.00 | 23 (85.2) | 89 (89.0) | 1.00 | ||||||||||||||
| Yes | 6 (15.0) | 9 (10.3) | 1.18 | 0.47–3.00 | 0.72 | 4 (14.8) | 11 (11.0) | 1.06 | 0.32–3.50 | 0.93 | ||||||||||
| Age | ||||||||||||||||||||
| ≤55 years | 19 (47.5) | 63 (72.4) | 1.00 | 14 (51.9) | 68 (68.0) | 1.00 | ||||||||||||||
| >55 years | 21 (52.5) | 24 (27.6) | 2.02 | 1.03–3.97 | <0.05 | 13 (48.1) | 32 (32.0) | 1.42 | 0.61–3.29 | 0.41 | ||||||||||
| Vegetable intake per day | ||||||||||||||||||||
| ≤1 serving | 21 (52.5) | 41 (47.1) | 1.00 | 15 (55.6) | 47 (47.0) | 1.00 | ||||||||||||||
| ≥2 servings | 19 (47.5) | 46 (52.9) | 0.85 | 0.44–1.64 | 0.66 | 12 (44.4) | 53 (53.0) | 0.72 | 0.31–1.67 | 0.44 | ||||||||||
HR, hazard ratio; AC→T, adriamycin + cyclophosphamide to docetaxel; TAC, docetaxel + adriamycin + cyclophosphamide; TCH, docetaxel + carboplatin + herceptin; TC, docetaxel + cyclophosphamide; PN, peripheral neuropathy.